Skip to main content

Table 1 Updates in ovarian cancer drug discovery demonstrating positive phase II activity

From: Updates on drug discovery in ovarian cancer

Category Agent/patent (manufacturer) Mechanism of action
Targeted agents VEGF-dependent angiogenesis inhibition Cediranib (AZD2171)/US20070135462 (AstraZeneca) Oral VEGFR-1,-2,-3 tyrosine kinase inhibitor
Nintedanib (BIBF1120)/US20140018405 (Boehringer Ingelheim) Oral VEGFR, PDGFR, FGFR tyrosine kinase inhibitor
PARP inhibitors Olaparib (AZD2281)/US2010098763 (AstraZeneca) Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor
Rucaparib (CO-338)/US8765751 (Clovis Oncology) Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor
Niraparib (MK-4827)/US20120035244 (Merck) Oral Poly (ADP-ribose) polymerase-1,-2 inhibitor
MEK inhibitors Selumetinib (AZD6244)/US8193229 (Array BioPharma/AstraZeneca) Oral inhibitor of MEK-1,-2
Binimetinib (MEK162)/US20130273061 (Array BioPharma/Novartis) Oral inhibitor of MEK-1,-2
Cytotoxic agents   Etirinotecan pegol (NKTR-102)/US20090074704 (Nektar) Inhibits Topoisomerase I (IV)
  Paclitaxel poliglumex (CT2103)/US20070167349 (CTI BioPharma) Mitotic inhibitor (IV)
Lurbinectedin (PM1183)/US20130266666 (PharmaMar) Marine-derived DNA minor groove binder (IV)
Therapeutic vaccines   Catumaxomab/US20120095192 (Trion Pharma) Oral tri-functional antibody binds EpCAM, CD3, and Fc receptor